(Q41151355)

27 September 2017

1 reference

title

New antidepressant drugs and the treatment of depression in the medically ill patient (English)

1 reference

27 September 2017

Stoudemire A

1

1 reference

27 September 2017

1 September 1996

1 reference

Psychiatric Clinics of North America

27 September 2017

1 reference

27 September 2017

19

1 reference

27 September 2017

495-514

1 reference

27 September 2017

3

1 reference

Possible interaction between fluoxetine and pimozide causing sinus bradycardia

27 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Abnormal platelet aggregation associated with fluoxetine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Dyskinesia associated with fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Fluoxetine and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Fluoxetine, fluvoxamine and extrapyramidal tract disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Fluoxetine-induced memory impairment in an adolescent

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

An interaction of sertraline and desipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Fluvoxamine-tricyclic antidepressant interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Pharmacokinetics of paroxetine in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Fluoxetine-associated dystonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Pharmacokinetics of the newer antidepressants: clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Interaction between carbamazepine and fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Drug interactions: Part I

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Elevation of plasma concentrations of haloperidol after the addition of fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Age, sex, and nitrazepam kinetics: relation to antipyrine disposition.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Fluoxetine impairs clearance of alprazolam but not of clonazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Increased carbamazepine plasma concentrations after fluoxetine coadministration

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Fluoxetine-pimozide interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Possible adverse drug interactions between fluoxetine and other psychotropics

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Fibrocystic breast disease following treatment with selective serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Fluoxetine: adverse effects and drug-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Studies on cytochrome P450 responsible for oxidative metabolism of imipramine in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Clinical pharmacokinetics of fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Treatment of acute depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Cardiovascular effects of bupropion in depressed patients with heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

The effect of fluoxetine on warfarin metabolism in the rat and man

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

A potential drug interaction between fluoxetine and valproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Toxic Interaction Between Fluvoxamine and Sustained Release Theophylline in an 11-Year-Old Boy

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Carbamazepine coadministration with fluoxetine or fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Increase of Parkinson disability after fluoxetine medication

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Potential terfenadine-fluoxetine interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Interaction of metoprolol and fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Clinical Implications of the Pharmacology of Sertraline

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

Extrapyramidal symptoms in a patient treated with fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970303-8

7 January 2021

10.1016/S0193-953X(05)70303-8

Identifiers

DOI

1 reference

release_t6nwaaiyh5eoflztwgx6hwfrny

27 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/t6nwaaiyh5eoflztwgx6hwfrny

24 November 2022

mapped directly with Wikidata item

PubMed ID

8856814

1 reference

PubMed ID

8856814